Company news
Aurinia Pharmaceuticals Inc news in 2021
Aurinia Pharmaceuticals Inc's news releases, calls and decks from 2021, newest first.
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
December 8, 2021
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 9, 2021
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
November 2, 2021
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
October 31, 2021
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
October 26, 2021
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
October 25, 2021
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
September 14, 2021
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 9, 2021
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
August 16, 2021
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
August 8, 2021
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 4, 2021
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
July 25, 2021
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
July 15, 2021
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
June 29, 2021
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
June 24, 2021
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
June 13, 2021
Aurinia Announces Results of the 2021 Annual General Meeting
June 6, 2021
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
June 6, 2021
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
May 19, 2021
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 13, 2021
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
May 9, 2021
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
May 9, 2021
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
May 5, 2021
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
April 27, 2021
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 14, 2021
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
April 7, 2021
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
March 14, 2021
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
March 1, 2021
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
February 23, 2021
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 17, 2021
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
February 16, 2021
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
January 21, 2021
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
January 7, 2021
Calls in 2021
Decks in 2021
- Technical Presentation (December 2021)
Technical · 10 slides · Dec 9, 2021